Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Product Portfolio
Our Process
Therapeutic Areas
Patient Assistance
Product Related Issues
About Us
Who We Are
Our Business
Diversity and Inclusion
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to Healthcare Professionals
Payments to Healthcare Organizations
Physician Payments - Sunshine Act
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2019
June
Media Release
/
Jun 03, 2019
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Read More
May
Media Release
/
May 24, 2019
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
Read More
Media Release
/
May 24, 2019
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Read More
Media Release
/
May 16, 2019
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Read More
Media Release
/
May 16, 2019
Five nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives
Read More
Media Release
/
May 11, 2019
Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination
Read More
Media Release
/
May 07, 2019
New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
Read More
Media Release
/
May 05, 2019
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
Read More
April
Media Release
/
Apr 15, 2019
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
Read More
Media Release
/
Apr 01, 2019
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
2
of 5
Page
3
of 5
Current page
4
of 5
Page
5
of 5
Page
6
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
You are here
Home
›
News
